A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin.
Title | A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin. |
Publication Type | Journal Article |
Year of Publication | 2016 |
Authors | Deming, Y, Xia, J, Cai, Y, Lord, J, Holmans, P, Bertelsen, S, Holtzman, D, Morris, JC, Bales, K, Pickering, EH, Kauwe, J, Goate, A, Cruchaga, C |
Corporate Authors | Alzheimer's Disease Neuroimaging Initiative (ADNI) |
Journal | Neurobiol Aging |
Volume | 37 |
Pagination | 208.e1-208.e9 |
Date Published | 2016 Jan |
ISSN | 1558-1497 |
Keywords | Aged, Aged, 80 and over, Alzheimer Disease, Apolipoprotein E4, Apolipoproteins E, Biomarkers, Clusterin, Endophenotypes, Female, Gene Ontology, Genome-Wide Association Study, Humans, Immunity, Male, Nerve Degeneration, Wound Healing |
Abstract | Genome-wide association studies have associated clusterin (CLU) variants with Alzheimer's disease (AD). However, the role of CLU on AD pathogenesis is not totally understood. We used cerebrospinal fluid (CSF) and plasma CLU levels as endophenotypes for genetic studies to understand the role of CLU in AD. CSF, but not plasma, CLU levels were significantly associated with AD status and CSF tau/amyloid-beta ratio, and highly correlated with CSF apolipoprotein E (APOE) levels. Several loci showed almost genome-wide significant associations including LINC00917 (p = 3.98 × 10(-7)) and interleukin 6 (IL6, p = 9.94 × 10(-6), in the entire data set and in the APOE ε4- individuals p = 7.40 × 10(-8)). Gene ontology analyses suggest that CSF CLU levels may be associated with wound healing and immune response which supports previous functional studies that demonstrated an association between CLU and IL6. CLU may play a role in AD by influencing immune system changes that have been observed in AD or by disrupting healing after neurodegeneration. |
DOI | 10.1016/j.neurobiolaging.2015.09.009 |
Alternate Journal | Neurobiol. Aging |
PubMed ID | 26545630 |
PubMed Central ID | PMC5118651 |
Grant List | MR/K013041/1 / / Medical Research Council / United Kingdom R01 AG044546 / AG / NIA NIH HHS / United States U24 AG021886 / AG / NIA NIH HHS / United States U01 AG032984 / AG / NIA NIH HHS / United States R01 AG042611 / AG / NIA NIH HHS / United States RF1 AG053303 / AG / NIA NIH HHS / United States U01 AG024904 / AG / NIA NIH HHS / United States G0300429 / / Medical Research Council / United Kingdom GR082604MA / / Wellcome Trust / United Kingdom P01 AG003991 / AG / NIA NIH HHS / United States P50 AG005681 / AG / NIA NIH HHS / United States P30 AG013846 / AG / NIA NIH HHS / United States P01 AG026276 / AG / NIA NIH HHS / United States #U01AG032984 / AG / NIA NIH HHS / United States P01AG03991 / AG / NIA NIH HHS / United States G0902227 / / Medical Research Council / United Kingdom MR/L501517/1 / / Medical Research Council / United Kingdom NIH P50 AG05681 / AG / NIA NIH HHS / United States P01-AG003991 / AG / NIA NIH HHS / United States A2013359S / / PHS HHS / United States TL1 TR000096 / TR / NCATS NIH HHS / United States R01-AG044546 / AG / NIA NIH HHS / United States MR/L010305/1 / / Medical Research Council / United Kingdom |